Organisational changes "critical to EMA's sustainability"
This article was originally published in Scrip
While the European Medicines Agency has proven effective in protecting human and animal health in the European region, the whole medicines authorisation system "is progressively attaining its maximum capacity", says a new report published by the European Commission. Thus, there is an urgent need for the agency to appropriately alter its organisation to ensure its sustainability in the face of novel challenges.
You may also be interested in...
The European Medicines Agency will use feedback from two workshops in September to clarify what data protection issues must be addressed to allow for the secondary use of health and medical data when it comes to developing, monitoring and evaluating medicines.
Although biological medicines carry a very low risk of being contaminated by nitrosamine impurities, the EMA says the possibility cannot be ruled out.
A new EU pilot will help drug regulators and policymakers understand the factors influencing the uneven availability of centrally authorized medicines in the member states.